The effect of combination therapy with interferon and cryofiltration on mesangial proliferative glomerulonephritis originating from mixed cryoglobulinemia in chronic hepatitis C virus infection.
Cryofiltration, which has developed from double filtration plasmapheresis (DFPP) with a cooling unit, is an on-line technique to remove cryoglobulin. We report on a patient who suffered from progressive edema and renal insufficiency caused by cryoglobulinemic membranoproliferative glomerulonephritis (MPGN), probably due to chronic hepatitis C virus (HCV) infection. To remove cryoglobulins and terminate the HCV infection, we utilized combination therapy with cryofiltration and interferon-alpha injection with corticosteroids. Interferon-alpha was capable of decreasing proteinuria but not diminishing cryoglobulin. Additional cryofiltration could remove cryoglobulin to an undetectable level. This combination therapy was partially successful to reduce proteinuria and prevent the progressive deterioration of renal function. The major adverse effects of this therapy were bleeding and myelosuppression. We conclude that this combination therapy may be effective and should be considered as treatment for cryoglobulinemic MPGN.
Kiyomoto
H
H
Second Department of Internal Medicine, Kagawa Medical University, Japan. kiyo@kms.ac.jp
Hitomi
H
H
Hosotani
Y
Y
Hashimoto
M
M
Uchida
K
K
Kurokouchi
K
K
Nagai
M
M
Takahashi
N
N
Fukunaga
M
M
Mizushige
K
K
Matsuo
H
H
Yuasa
S
S
D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003449:Cryoglobulinemia / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D015432:Glomerulonephritis, Membranoproliferative / Q000209:etiology* / Q000473:pathology / Q000628:therapy*; D017583:Hemodiafiltration / Q000379:methods*; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D010956:Plasmapheresis / Q000379:methods*; D016896:Treatment Outcome
D000998:Antiviral Agents; D016898:Interferon-alpha